A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects With Gaucher Disease (GALILEO-2)
Latest Information Update: 07 Feb 2025
At a glance
- Drugs FLT 201 (Primary)
- Indications Gaucher's disease; Gaucher's disease type I
- Focus Adverse reactions
- Acronyms GALILEO-2
- Sponsors Spur Therapeutics
Most Recent Events
- 04 Feb 2025 According to a Spur Therapeutics media release, data from this study will be showcased this week in oral and poster presentations at the 21st Annual WORLDSymposium.
- 13 Aug 2024 New trial record